- Home
- WING vs IONS Comparison
WING vs IONS Comparison
Compare WING & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WING
- IONS
- Stock Information
- Founded
- WING 1994
- IONS 1989
- Country
- WING United States
- IONS United States
- Employees
- WING N/A
- IONS N/A
- Industry
- WING Restaurants
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- WING Consumer Discretionary
- IONS Health Care
- Exchange
- WING Nasdaq
- IONS Nasdaq
- Market Cap
- WING 6.1B
- IONS 6.0B
- IPO Year
- WING 2015
- IONS 1991
- Fundamental
- Price
- WING $224.67
- IONS $30.03
- Analyst Decision
- WING Buy
- IONS Buy
- Analyst Count
- WING 19
- IONS 18
- Target Price
- WING $349.79
- IONS $60.50
- AVG Volume (30 Days)
- WING 825.7K
- IONS 1.5M
- Earning Date
- WING 04-30-2025
- IONS 05-06-2025
- Dividend Yield
- WING 0.48%
- IONS N/A
- EPS Growth
- WING 57.45
- IONS N/A
- EPS
- WING 3.70
- IONS N/A
- Revenue
- WING $625,807,000.00
- IONS $705,138,000.00
- Revenue This Year
- WING $19.92
- IONS N/A
- Revenue Next Year
- WING $17.55
- IONS $25.98
- P/E Ratio
- WING $60.54
- IONS N/A
- Revenue Growth
- WING 36.03
- IONS N/A
- 52 Week Low
- WING $205.60
- IONS $30.23
- 52 Week High
- WING $433.86
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- WING 45.56
- IONS 36.51
- Support Level
- WING $219.00
- IONS $31.04
- Resistance Level
- WING $233.59
- IONS $33.76
- Average True Range (ATR)
- WING 8.35
- IONS 1.16
- MACD
- WING 3.81
- IONS -0.31
- Stochastic Oscillator
- WING 68.14
- IONS 8.19
About WING Wingstop Inc.
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, reaching north of 2,560 global stores at the end of 2024. With a 98% franchised model, Wingstop generates the lion share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.